Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Fludarabine and Melphalan Results in Fewer Relapses Compared to Fludarabine and Targeted Busulfan in Patients Receiving Reduced Intensity Conditioning for AML and MDS

Ryan James Caddell, PharmD, Braydon Schaible, MPH, Zhenjun Ma, PhD, Elizabeth Dimaggio, PharmD, BCOP, Rebecca Tombleson, PharmD, BCOP, Claudio Anasetti, MD, Ernesto Ayala, MD, Brian C. Betts, MD, Mohamed A. Kharfan-Dabaja, MD, Frederick L. Locke, MD, Taiga Nishihori, MD, Joseph A. Pidala, MD, Hugo F. Fernandez, MD, Asmita Mishra, MD

Blood (2016) 128 (22): 3486.

https://doi.org/10.1182/blood.V128.22.3486.3486

Published: 2016

Journal Articles

A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT)

Blood (2016) 128 (22): 505.

https://doi.org/10.1182/blood.V128.22.505.505

Published: 2016

Journal Articles

Unrelated Male Donors Versus Sibling Parous Female Donors: Impact on Transplant-Related Outcomes

Anita J Kumar, MDMS, Soyoung Kim, PhD, Michael Hemmer, MS, Mukta Arora, MD, Steve Spellman, MBS, Joseph A. Pidala, MD, Daniel Couriel, MD MS, Amin M. Alousi, MD, Alison W Loren, MD MS

Blood (2016) 128 (22): 70.

https://doi.org/10.1182/blood.V128.22.70.70

Published: 2016

Journal Articles

Influence of Age on Risk for Acute and Chronic Graft Versus Host Disease in Children Receiving HLA Identical Sibling Bone Marrow Transplantation

Muna Qayed, MD MSc, John Horan, MD MPH, Stephen R. Spellman, MBS, Mukta Arora, MD, Tao Wang, PhD, Michael Hemmer, MS, Joseph A Pidala, MD, PhD, Daniel Couriel, MD MS, Amin M. Alousi, MD

Blood (2016) 128 (22): 2228.

https://doi.org/10.1182/blood.V128.22.2228.2228

Published: 2016

Journal Articles

Upper Gastrointestinal Acute Graft-Versus-Host Disease Adds Minimal Prognostic Value When Present in Isolation or in Addition to Grade I or Other Grade II-Defining GvHD Manifestations

Sarah Nikiforow, MD PhD, Michael Hemmer, MS, Stephen R. Spellman, MBS, Amin M. Alousi, MD, Daniel R. Couriel, MD, Joseph A Pidala, MD, PhD, Mukta Arora, MD, Corey S Cutler, MD MPH, Tao Wang, PhD

Blood (2015) 126 (23): 857.

https://doi.org/10.1182/blood.V126.23.857.857

Published: 2015

Journal Articles

CD4 Treg and CD4 Tcon Utilize Distinct TCR Vbeta Repertoires in Response to Alloantigen

Anandharaman Veerapathran, PhD, Micheal Schell, PhD, Francisca Beato, B.S, TzuHua Juan, MPH, Sean Yoder, M.S, Brian C Betts, MD, Joseph A Pidala, MD, PhD, Claudio Anasetti, MD

Blood (2015) 126 (23): 4286.

https://doi.org/10.1182/blood.V126.23.4286.4286

Published: 2015

Journal Articles

Impact of Splenomegaly in the Presence of Negative PET FDG Avidity on Allogeneic Hematopoietic Cell Transplant Outcomes in Patients with Lymphoid Malignancies

Farhad Khimani, MD, Daniel K. Jeong, MD, Taiga Nishihori, MD, Ernesto Ayala, MD, Joseph A Pidala, MD, PhD, Frederick L. Locke, MD, Gage Kenneth, Julio C. Chavez, MD, Claudio Anasetti, MD, Mohamed A. Kharfan-Dabaja, MD

Blood (2015) 126 (23): 5524.

https://doi.org/10.1182/blood.V126.23.5524.5524

Published: 2015

Journal Articles

Body Composition Predicts Survival in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Recipients

Asmita Mishra, MD, Binglin Yue, Martine Extermann, MD PhD, Claudio Anasetti, MD, Heather Jim, Jongphil Kim, Joseph A Pidala, MD, PhD, Vickie E Baracos

Blood (2015) 126 (23): 2113.

https://doi.org/10.1182/blood.V126.23.2113.2113

Published: 2015

Journal Articles

An International Multicenter Comparative Analysis of Tacrolimus Plus Sirolimus with or without Antithymocyte Globulin As Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation

Mohamed A. Kharfan-Dabaja, MD, Rocio Parody, MD, Janelle Perkins, PharmD, Oriana Lopez-Godino, MD, Lucia Lopez-Corral, MD, Lourdes Vazquez, MD, Dolores Caballero, MD, Jose Falantes, MD, Jamie Shapiro, PharmD, Guillermo Orti, MD, Pere Barba, MD, David Valcárcel, MD PhD, Alber Esquirol, MD, Rodrigo Martino, MD PhD, Jose Luis Piñana, MD, Carlos Solano, MD, Joseph A Pidala, MD, PhD, Claudio Anasetti, MD, Jose A. Perez-Simon, MD, PhD

Blood (2015) 126 (23): 3142.

https://doi.org/10.1182/blood.V126.23.3142.3142

Published: 2015

Journal Articles

CD4+ T-Cell STAT3 Activity Is Increased before Acute Graft-Versus-Host Disease Onset and Its Pharmacologic Inhibition Selectively Controls Alloresponses

Brian C Betts, MD, Anandharaman Veerapathran, PhD, Francisca Beato, BS, Harshani R Lawrence, PhD, Said M Sebti, PhD, Joseph A Pidala, MD, Claudio Anasetti, MD

Blood (2014) 124 (21): 3819.

https://doi.org/10.1182/blood.V124.21.3819.3819

Published: 2014

Journal Articles

Targeted Intravenous Busulfan and Fludarabine Allogeneic Transplantation Conditioning in Acute Myeloid Leukemia.

Joseph A. Pidala, MD, Jongphil Kim, PhD, Claudio Anasetti, MD, Melissa Alsina, MD, Ernesto Ayala, MD, Teresa Field, MD, PhD, Mohamed A Kharfan-Dabaja, MD, Jose L Ochoa, MD, Lia Perez, MD, Janelle Perkins, PharmD, Marcie Tomblyn, MD, MS, Hugo F. Fernandez, MD

Blood (2009) 114 (22): 2290.

https://doi.org/10.1182/blood.V114.22.2290.2290

Published: 2009

Journal Articles

Sirolimus Yields High Response Rates in Hematopoietic Allograft Recipients with Steroid-Refractory Acute Graft-Versus-Host Disease.

Joseph A. Pidala, MD, Daanish Hoda, Norma Salgado-Vila, Jongphil Kim, PhD, Janelle Perkins, PharmD, Ryan Bookout, PharmD, Teresa Field, MD, PhD, Lia Perez, MD, Ernesto Ayala, MD, J. Leonel Ochoa-Bayona, Jyotishankar Raychaudhuri, Melissa Alsina, MD, John N Greene, MD, William E. Janssen, PhD, Hugo F. Fernandez, MD, Claudio Anasetti, MD, Mohamed A Kharfan-Dabaja, MD

Blood (2009) 114 (22): 2235.

https://doi.org/10.1182/blood.V114.22.2235.2235

Published: 2009

NARROW

Fludarabine and Melphalan Results in Fewer Relapses Compared to Fludarabine and Targeted Busulfan in Patients Receiving Reduced Intensity Conditioning for AML and MDS

A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT)

Unrelated Male Donors Versus Sibling Parous Female Donors: Impact on Transplant-Related Outcomes

Influence of Age on Risk for Acute and Chronic Graft Versus Host Disease in Children Receiving HLA Identical Sibling Bone Marrow Transplantation

Upper Gastrointestinal Acute Graft-Versus-Host Disease Adds Minimal Prognostic Value When Present in Isolation or in Addition to Grade I or Other Grade II-Defining GvHD Manifestations

CD4 Treg and CD4 Tcon Utilize Distinct TCR Vbeta Repertoires in Response to Alloantigen

Impact of Splenomegaly in the Presence of Negative PET FDG Avidity on Allogeneic Hematopoietic Cell Transplant Outcomes in Patients with Lymphoid Malignancies

Body Composition Predicts Survival in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Recipients

An International Multicenter Comparative Analysis of Tacrolimus Plus Sirolimus with or without Antithymocyte Globulin As Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation

CD4+ T-Cell STAT3 Activity Is Increased before Acute Graft-Versus-Host Disease Onset and Its Pharmacologic Inhibition Selectively Controls Alloresponses

Targeted Intravenous Busulfan and Fludarabine Allogeneic Transplantation Conditioning in Acute Myeloid Leukemia.

Sirolimus Yields High Response Rates in Hematopoietic Allograft Recipients with Steroid-Refractory Acute Graft-Versus-Host Disease.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only